The total compensation for Johnson & Johnson is US$4.69 billion, which is the highest compensation amount in the talcum rights protection case so far. Johnson & Johnson shares fell 1.4%.
The trial of the case lasted more than five weeks, and the jury heard the testimony of nearly 12 experts from both the prosecution and the defense before making a judgment.
Twenty-two women and their families said they had used Johnson's baby powder and other talc-containing beauty products for a long time. They accused Johnson, who had known at least since the 1970s that their products contained asbestos but did not warn consumers.
Johnson & Johnson currently faces approximately 9,000 similar lawsuits.
In 2012, the St. Louis Court of Missouri, USA, ruled that Johnson and Johnson paid a $106 million female in Virginia. The woman was diagnosed with ovarian cancer in 2012.
In February 2016, Johnson was sentenced to pay $72 million to the family of Jacqueline Fox, Alabama, who died of ovarian cancer, and her death was believed to be associated with a baby powder and shower gel that continued to use Johnson.
In the same year, a jury in St. Louis, USA, ruled that Johnson & Johnson had compensated an ovarian cancer patient for $55 million. The plaintiff in the case was a woman who had to have her uterus removed because of ovarian cancer.
In August 2017, a woman sued talcum powder in Johnson's baby powder to cause ovarian cancer. Johnson & Johnson was awarded US$417 million (approximately RMB 2.78 billion).
However, in the subsequent appeals of Johnson & Johnson, there were often cases in which the court overturned the high-priced penalty judgment.
In many previous lawsuits, Johnson & Johnson always insisted that the relationship between ovarian cancer and talcum powder was not found through comprehensive research. In a statement, Johnson & Johnson spokesman Goodrich said that although the company is sympathetic to patients affected by ovarian cancer, science supports the safety of Johnson's baby powder. Goodrich said the company is preparing for other trials in the United States and will continue to defend the safety of its products.